Therapeuticsmd Inc Stock Price, News & Analysis

Galderma, the largest independent dermatology company, announced the appointment of Karen L. Ling to its Advisory Committee, effective March 1, 2022. Ms. Ling brings over 25 years of global human resources experience from executive positions at AIG, Allergan, Merck, and Wyeth, focusing on talent management and organizational culture. Currently, she serves on the Boards of iRhythm Technologies (NASDAQ: IRTC) and TherapeuticsMD (NASDAQ: TXMD). Both Thomas Ebeling and Flemming Ørnskov expressed enthusiasm about her joining, highlighting her strengths in human capital management and diversity initiatives.

TherapeuticsMD, Inc. (NASDAQ:TXMD) announced that the FDA denied proposed revisions to the manufacturing testing limits for ANNOVERA through a Supplemental New Drug Application (sNDA). The FDA provided recommendations for further information to support future revisions. As a result, the company will continue to supply ANNOVERA under the existing manufacturing specifications approved in its original NDA. ANNOVERA is recognized as a long-lasting, reversible birth control option approved by the FDA in August 2018.

TherapeuticsMD, Inc. (NASDAQ: TXMD) has settled its U.S. patent litigation concerning BIJUVA® with Amneal Pharmaceuticals. The settlement allows Amneal to commercially launch its generic version of BIJUVA by May 25, 2032, or sooner under specific conditions. The litigation had been ongoing since 2020 and stemmed from Amneal's attempt to market a generic variant before the patent expiration date of November 21, 2032. CEO Rob Finizio emphasizes the strength of the patent estate for BIJUVA, despite the early settlement.

TherapeuticsMD, Inc. (TXMD) reported Q3 2021 financial results, showing a total net product revenue of $24.5 million, up 41.1% from Q3 2020. ANNOVERA prescriptions rose by 62.7%, totaling 8,351 prescriptions. The company plans a $40 million cost reduction initiative for 2022, with an additional $20 million expected from divesting vitaCare. Hugh O'Dowd is appointed CEO. Despite revenue growth, the net loss increased to $47.4 million. Manufacturing issues related to ANNOVERA could impact future revenue covenants.

TherapeuticsMD has announced significant leadership changes, appointing Hugh O’Dowd as the new Chief Executive Officer, effective on or before December 31, 2021. He succeeds Robert G. Finizio, who will transition to Vice Chair of the Board. O’Dowd, previously President and CEO of Neon Therapeutics, has a strong track record in the pharmaceutical industry. Finizio expressed confidence in O’Dowd's capabilities to advance the company’s growth and mission in women’s healthcare, addressing unique challenges throughout various life stages.

TherapeuticsMD, Inc. (NASDAQ: TXMD) will announce its third quarter 2021 financial results on November 11, 2021, before U.S. markets open. A conference call is scheduled for 8:30 a.m. ET on the same day, providing insights into the results and business updates. Investors can access the call by dialing 866-665-9531 (US) or 724-987-6977 (international) with Conference ID 6341637. A live webcast will also be available on the company's website, with a replay accessible for 30 days.

TherapeuticsMD, Inc. (NASDAQ: TXMD) has appointed Mark Glickman as its new Chief Business Officer. Glickman, who has extensive experience in commercial roles at various pharmaceutical companies, will receive 660,000 restricted stock units (RSUs) and 260,000 performance stock units (PSUs) as part of his inducement package. The RSUs will vest over three years, while the PSUs are tied to revenue performance metrics. The appointment is part of the company's strategy to strengthen its leadership in women's healthcare.

Theramex has launched Bijuva® / Bijuve® (1mg estradiol / 100mg progesterone) in Europe and the UK. This body-identical hormone therapy is the first of its kind for post-menopausal women with intact uterus, aimed at alleviating symptoms of estrogen deficiency. Unlike synthetic hormones, Bijuva® and Bijuve® are chemically identical to natural hormones, associated with lower health risks. Clinical trials show significant improvements in vasomotor symptoms and quality of life during treatment, making it a vital option for women seeking effective HRT.

TherapeuticsMD, Inc. (NASDAQ: TXMD) is recognizing Menopause Awareness Month to empower the 64 million U.S. women currently in menopause. With over 80% experiencing symptoms, the company highlights vulvar and vaginal atrophy (VVA), affecting more than half of menopausal women. The 'Take Pause' initiative includes educational videos featuring Dr. Rebecca Brightman to raise awareness about VVA and available treatments such as IMVEXXY. This effort aims to normalize discussions around menopause and its symptoms, encouraging women to seek care.